Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

AUTH/3425/11/20 & AUTH/3426/11/20: RCGP Overdiagnosis Group complaint about Eliquis AF pulse-check email (No breach)

RCGP Overdiagnosis Group challenged a Pfizer/BMS Eliquis email promoting AF pulse checks at flu clinics for over-65s, alleging…

8 Mar 2026

LEO Pharma voluntary admission: undisclosed 2019 transfers of value to patient organisations (AUTH/3527/6/21)

LEO discovered four cross-border transfers of value involving three UK patient organisations. Three 2019 payments were disclosed late…

8 Mar 2026

Teva: Ajovy website landing-page pop-up – no breach (AUTH/3602/1/22)

A UK health professional complained that the Ajovy website entry pop-up lacked the generic name and black triangle.…

8 Mar 2026

AstraZeneca breach over Trixeo ad implying mortality benefit (Pulse magazine)

Pulse ad for Trixeo linked COPD exacerbations and death with a β€œTake action with Trixeo” call-to-action, creating an…

8 Mar 2026

AUTH/3728/1/23: Complainant v Bristol Myers Squibb – alleged promotion of Zeposia (ozanimod hydrochloride) (No breach / not within scope)

PMCPA case AUTH/3728/1/23: complaint alleging promotion of Zeposia (ozanimod hydrochloride) against Bristol Myers Squibb. Outcome: no breach; matter…

8 Mar 2026

AUTH/3896/5/24: Complainant v Roche β€” patient organisation materials and declaration of involvement (No breach)

Complaint alleged Roche funding wasn’t declared β€œfrom the outset” on patient organisation programme webpages/materials. Panel found complainant hadn’t…

8 Mar 2026

Meda Pharmaceuticals: concerns about call/contact rate expectations and alleged off-licence promotion of Aldara

An anonymous representative alleged pressure to promote Aldara off-licence and raised concerns about call-rate targets and a GP…

8 Mar 2026

AstraZeneca v Novartis: Femara press release headline overstated overall survival benefit

Novartis’ UK press release headline implied an overall survival benefit for Femara vs tamoxifen despite non-significant ITT results…

8 Mar 2026

AUTH/2226/4/09: Merz Pharma v Allergan β€” Botox product monograph comparisons (misleading and unsubstantiated claims; failure to provide substantiation)

Allergan’s Botox monograph made comparative claims vs Dysport (and referenced Xeomin). Panel found several claims misleading/unsubstantiated and ruled…

8 Mar 2026

AUTH/2328/7/10: Trust Clinical Director v Pfizer – conduct of representative (no breach)

A trust clinical director alleged a Pfizer rep was intimidating and applied inappropriate pressure when trying to access…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training